Alnylam Pharmaceuticals
Get verified emails for Alnylam Pharmaceuticals employeesAbout Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, founded in 2002. It pioneered RNA interference (RNAi) therapeutics, a treatment approach designed to silence genes that cause or contribute to disease. Over more than two decades, the company says its research has helped establish the field of RNAi therapeutics.
Alnylam develops and commercializes RNAi medicines for both rare and prevalent diseases. Its first commercial medicine, approved in 2018, was the world’s first RNAi therapeutic, and the company has since had five additional Alnylam-developed medicines approved. New therapies remain in development. Through its global organization, the company also provides products and related medical information support.
The company employs more than 2,600 people and operates offices across North America, Europe, Asia, and South America. Alnylam was founded by a group of researchers and biotech leaders and serves a global patient and healthcare community through its medicines and ongoing drug development efforts.
Need to reach the Alnylam Pharmaceuticals team directly? Find verified work emails for every employee with Snov.io
Insights
Updated 31 Aug 2026Alnylam is under both competitive and reputational pressure in heart disease after an AstraZeneca trial failure drew fresh attention to the ATTR-CM market, and STAT reported that the company is now defending its medicines. A short line says a lot. At the same time, new ESC Congress 2026 data are being used to reinforce the clinical profile of vutrisiran (AMVUTTRA) across ATTR patient populations and treatment settings, which points to a deliberate effort to lean on evidence generation to protect and expand its cardiovascular franchise.
The strategic focus seems clear: Alnylam is deepening its RNAi-powered TTR-silencing position in ATTR-CM and related cardiovascular indications. One presentation stood out. At ESC, subgroup analyses from HELIOS-B showed consistent clinical benefit across all-cause mortality and recurrent cardiovascular events, and Alnylam said the findings reinforce the strength of RNAi-powered silencing for cardiovascular disease while widening the potential use of AMVUTTRA.
Investor sentiment looks mixed, but it is still active. Alnylam was named among biotech stocks to watch, and one filing said Nissay Asset Management Corp Japan increased its Alnylam stake in the second quarter, which suggests the market is still paying close attention even as the company works through competitive pressure in heart disease.
Frequently asked questions
Alnylam Pharmaceuticals is headquartered in Cambridge, Massachusetts, United States.
Alnylam Pharmaceuticals has 1001-5000 employees according to its company profile.
Alnylam Pharmaceuticals operates in the Biotechnology sector. Public valuation figures are not always disclosed for private companies.